Skip to main content
Publications
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Sussman G, Lynde C, Zanganeh S, Lacuesta G, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA, McBride DW, Westlund RE, Sweeney CT, Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: an analysis of the diagnosis and treatment of patients with antihistamine-refractory CSU. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada. [abstract] Clin Transl Allergy. 2015 Aug 17; 5(29):1-7. doi: 10.1186/s13601-015-0072-9
Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk M, Bérard F, Sussman G, Giménez-Arnau AM, Ortiz De Frutos J, Knulst A, Canonica GW, Hollis K, McBride D, Balp MM. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy. 2015 Aug 17;17(5):29.